Search

Elexacaftor

Elexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. It received FDA approval in October 2019 in combination with tezacaftor and ivacaft...

Gadoxetic acid

Ethoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up the drug.

Zolmitriptan

[A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997.

Crizanlizumab

It was developed by Novartis and was granted FDA approval on November 15, 2019.

Hydroxychloroquine

[A192132] **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020. … [L14312]** Hydroxychloroquine was granted FDA approval on 18 April 1955.[L8072] A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.[A192546]

Setmelanotide

[A224449] Imcivree was granted EMA orphan designation on November 19, 2018 [L24559] and FDA approval on November 25, 2020.[L24429] On May 4, 2023, it was approved by Health Canada.[L46327]

FAV-201

FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.

Arzoxifene

Thiotepa

It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.

Dexchlorpheniramine

It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.